Active Ingredient: Rurioctocog alfa pegol
Treatment and prophylaxis of bleeding in patients 12 years and above with haemophilia A (congenital factor VIII deficiency).
For this indication, competent medicine agencies globally authorize below treatments:
Intravenous
40 - 50 [iU] per kg of body weight
From 40 To 50 [iU] per kg of body weight once every 3 day(s)
The safety and efficacy of rurioctocog alfa pegol in previously untreated patients have not yet been established.
No data are available.
During the course of treatment, appropriate determination of factor VIII levels is advised to guide the dose to be administered and the frequency of repeated infusions. Individual patients may vary in their response to factor VIII, demonstrating different half-lives and recoveries. Dose based on bodyweight may require adjustment in underweight or overweight patients. In the case of major surgical interventions in particular, precise monitoring of the substitution therapy by means of coagulation analysis (plasma factor VIII activity) is indispensable.
A field study has indicated that plasma factor VIII levels can be monitored using either a chromogenic substrate assay or a one stage clotting assay routinely used in clinical laboratories.
The dose and duration of the substitution therapy depend on the severity of the factor VIII deficiency, on the location and extent of the bleeding and on the patient’s clinical condition.
The number of units of factor VIII administered is expressed in International Units (IU), which are related to the current WHO concentrate standard for factor VIII products. Factor VIII activity in plasma is expressed either as a percentage (relative to normal human plasma) or preferably in International Units (relative to an International Standard for factor VIII in plasma).
One International Unit (IU) of factor VIII activity is equivalent to that quantity of factor VIII in one ml of normal human plasma.
The calculation of the required dose of factor VIII is based on the empirical finding that 1 IU factor VIII per kg body weight raises the plasma factor VIII activity by 2 IU/dl. The required dose is determined using the following formula:
Required international units (IU) = body weight (kg) x desired factor VIII rise (%) x 0.5
The amount to be administered and the frequency of administration should always be oriented to the clinical effectiveness in the individual case.
In the case of the following haemorrhagic events, factor VIII activity should not fall below the given plasma activity level (in % of normal or IU/dl) in the corresponding period.
The following Table 1 can be used to guide dosing in bleeding episodes and surgery.
Table 1. Guide for dosing in bleeding episodes and surgery:
| Degree of haemorrhage/type of surgical procedure | Factor VIII level required (% or IU/dl) | Frequency of doses (hours)/duration of therapy (days) |
|---|---|---|
| Haemorrhage | ||
| Early haemarthrosis, muscle bleeding or oral bleeding. | 20–40 | Repeat injections every 12 to 24 hours. At least 1 day, until the bleeding episode, as indicated by pain, is resolved or healing is achieved. |
| More extensive haemarthrosis, muscle bleeding or haematoma | 30–60 | Repeat injections every 12 to 24 hours for 3–4 days or more until pain and acute disability are resolved. |
| Life threatening haemorrhages. | 60–100 | Repeat injections every 8 to 24 hours until threat is resolved. |
| Surgery | ||
| Minor Including tooth extraction. | 30–60 | Every 24 hours at least 1 day, until healing is achieved. |
| Major | 80–100 (pre- and postoperative) | Repeat injections every 8 to 24 hours until adequate wound healing, then continue therapy for at least another 7 days to maintain a factor VIII activity of 30% to 60% (IU/dl). |
For long term prophylaxis, the recommended dose is 40 to 50 IU of rurioctocog alfa pegol per kg bodyweight twice weekly in 3 to 4 day intervals. Adjustments of doses and administration intervals may be considered based on achieved FVIII levels and individual bleeding tendency.
On demand treatment dosing in paediatric patients (12 to 18 years of age) is the same as for adult patients. Prophylactic treatment for patients from 12 to <18 years is the same as for adult patients. The long-term safety of rurioctocog alfa pegol in children below 12 years has not yet been established. Adjustments of doses and administration intervals may be considered based on achieved FVIII levels and individual bleeding tendency.
Rurioctocog alfa pegol is for intravenous use. The rate of administration should be determined to ensure the comfort of the patient up to a maximum of 10 ml/min.
Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.
